New York company, Emendo Biotherapeutics, has raised $61 million in Series B funding to accelerate its novel gene editing platform into a broad therapeutic product pipeline.
The investment round was led by Japanese biopharma, AnGes, and included participation from OrbiMed Advisors and Takeda Ventures.
“This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene editing platform towards a broad clinical pipeline for addressing devastating untreatable diseases,” said Dr. David Baram, President & CEO of Emendo Biotherapeutics.
OMNI is a next-gen allele-specific gene editing platform that uses synthetic biology to expand what is possible in genome-editing.
In 2019, Emendo granted an option to Takeda to use the OMNI nuclease gene editing program for two research and development targets. Emendo received an undisclosed investment from Takeda Ventures that was converted in the Series B.